European markets have recently experienced volatility, influenced by rising oil prices and elevated sovereign bond yields, which have tempered investor risk appetite. With inflation pressures building across the region, investors are increasingly focused on companies that not only demonstrate growth potential but also show strong insider ownership—an indicator of confidence in a company's future prospects.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 12.1% | 39.8% |
| Kuros Biosciences (SWX:KURN) | 23.7% | 65.8% |
| KebNi (OM:KEBNI B) | 16.3% | 103.8% |
| Gold Road International (OB:GOLDR) | 35.9% | 89.8% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 19.4% | 41.1% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| BioArctic (OM:BIOA B) | 32% | 67.1% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
| 2G Energy (XTRA:2GB) | 13.4% | 30.2% |
Let's uncover some gems from our specialized screener.
Med Life (BVB:M)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Med Life S.A. is a private healthcare provider offering integrated medical services through its clinics and hospitals in Romania, with a market cap of RON5.86 billion.
Operations: The company's revenue segments include Clinics (RON1.27 billion), Corporate (RON332.30 million), Hospitals (RON919.37 million), Pharmacies (RON91.13 million), Stomatology (RON119.82 million), and Laboratories (RON373.81 million).
Insider Ownership: 36.5%
Med Life S.A. demonstrates strong growth potential with revenue expected to increase at 9.8% annually, outpacing the market average of 5.4%. Despite a current net loss of RON 27.8 million for H1 2026, it is forecasted to achieve profitability within three years, reflecting above-market profit growth expectations. The stock trades at a significant discount to its estimated fair value and does not exhibit substantial recent insider trading activities, suggesting stable insider confidence in its future prospects.
- Navigate through the intricacies of Med Life with our comprehensive analyst estimates report here.
- Our valuation report here indicates Med Life may be undervalued.
Sanoma Oyj (HLSE:SANOMA)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Sanoma Oyj is a media and learning company with operations in Finland, the Netherlands, Poland, Spain, Belgium, Italy, and internationally; it has a market cap of €1.63 billion.
Operations: The company's revenue is primarily derived from its Learning segment, which accounts for €754.80 million, and its Media Finland segment, contributing €542.90 million.
Insider Ownership: 16.5%
Sanoma Oyj's earnings are projected to grow significantly at 25.6% annually, surpassing the Finnish market average of 14.6%, although revenue growth is anticipated to lag behind the market. The company carries a high debt level and its profit margins have decreased from last year, now at 1.3%. Recent changes in its Shareholders' Nomination Committee reflect shifts in major shareholder positions, potentially impacting future strategic decisions.
- Take a closer look at Sanoma Oyj's potential here in our earnings growth report.
- According our valuation report, there's an indication that Sanoma Oyj's share price might be on the expensive side.
AlzChem Group (XTRA:ACT0)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: AlzChem Group AG, with a market cap of €1.62 billion, develops, produces, and markets a range of chemical specialties across Germany, the European Union, other parts of Europe, Asia, the NAFTA region, and internationally.
Operations: The company's revenue is primarily derived from Specialty Chemicals, contributing €398.39 million, and Basics & Intermediates, which accounts for €152.20 million.
Insider Ownership: 15.5%
AlzChem Group's earnings are forecast to grow at 19.7% annually, outpacing the German market average of 14.7%, with revenue expected to rise by 11.5% per year. Despite being removed and re-added to the Germany SDAX Index recently, it trades significantly below its estimated fair value, suggesting potential undervaluation. The company reported solid financials for H1 2026 with increased sales and net income, indicating robust operational performance amid fluctuating index status.
- Click here and access our complete growth analysis report to understand the dynamics of AlzChem Group.
- Our expertly prepared valuation report AlzChem Group implies its share price may be lower than expected.
Key Takeaways
- Get an in-depth perspective on all 199 Fast Growing European Companies With High Insider Ownership by using our screener here.
- Searching for a Fresh Perspective? The end of cancer? These 35 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com